• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail

Pure Home Air 14-Jan-04

Department of Health and Human Services' logoDepartment of Health and Human Services

Public Health Service
Food and Drug Administration


Center for Devices and Radiological Health
2038 Gaither Road
Rockville, MD 20850



JAN 14, 2004

Mr. John R. Garrett
President & CEO
Pure Home Air
28494 Westinghouse Place
Suite #314
Valencia, California 91355

Dear Mr. Garrett:

The Food and Drug Administration (FDA) has obtained information from your Internet web site, <http://www.purehomeair.com>, that reveals a serious regulatory problem involving the Biozone Air Purifier, which is commercially distributed by your firm.

Your web site states that, "Being previously unrecognized, there have been no specific tests on mechanical methods of destruction of the SARS virus. However, there have been extensive studies on the destruction of similar viruses that cause influenza and pneumonia. It would be scientifically rational to assume that methods used to destroy these viruses and others would also be effective on the SARS virus." Consequently, the Biozone Air Purifier is intended for use in the cure, mitigation, treatment, or prevention of disease within the meaning of section 201(h) of the Federal Food, Drug, and Cosmetic Act (Act), 21 U.S.C.321(h), and is a medical device that is subject to the Act's requirements for Premarket approval or clearance by FDA.

Our records do not show that approval or clearance has been obtained for the Biozone Air Purifier to prevent SARS transmission or for any other SARS-related indication. Accordingly, the product is adulterated under section 501(f)(1)(B) of the Act (21 U.S.C.351(f)(1)(B)), in that it is a class III device under section 513(f)(21 U.S.C.360c(f)) and you do not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a)(21 U.S.C.360e(a)) or an approved application for investigational device exemption under section 520(g)(21 U.S.C.360j(g)). The product is also misbranded under section 502(o)(21 U.S.C.352(o)), because a notice or other information respecting it was not provided to the FDA as required by section 510(k) (21 U.S.C.360(k)). For a product requiring premarket approval (as opposed to clearance), the notification required by section 510(k) is deemed to be satisfied when a PMA is pending before the agency. 21 CFR 807.81(b).

This serious violation of the law may result in the FDA taking regulatory action without further notice to you. Such action can include, but is not limited to, seizing your product inventory, obtaining a court injunction against further marketing your products, or seeking civil money penalties. Also, Federal agencies are informed about the Warning Letters we issue, such as this one, so that they may consider this information when awarding government contracts.

Please respond in writing, within 15 days of receiving this letter, by explaining the specific steps you have taken to correct this violation and to assure that similar violations will not occur. If you need additional time, please explain the reason for the delay and advise us when you expect to respond.

Please address your response to Ms. Betty Collins, Director, Division of Enforcement A, Office of Compliance, Center for Devices and Radiological Health, Food and Drug Administration, 2098 Gaither Road (HFZ-320), Rockville, Maryland 20850. If you have any questions concerning the contents of this letter, you may contact Carolyn Niebauer, Chief, General Hospital Devices Branch, or Diane Goldsberry, Technical Information Specialist, by phone at (301)594-4618 or by facsimile at (301)594-4638.

You should understand that there are many FDA requirements pertaining to the manufacture and marketing of medical devices. This letter pertains only to the issue of premarket clearance or approval for your devices and does not necessarily address other obligations you have under the Act. You may obtain general information about FDA requirements for medical devices by contacting our Division of Small Manufacturers, International and Consumer Assistance at 1-800-638-2041 or through the Internet at <http://www.fda.gov>.

Finally, in addition to the Act, you may be subject to the Federal Trade Commission Act, which is administered by the Federal Trade Commission (FTC). A copy of this letter is being forwarded to the FTC.

Timothy A. Ulatowski
Office of Compliance
Center for Devices and
Radiological Health